Proyecto Cel.Obert: una intervención educativa para la biblioteca Bon Pastor

Cel.Obert es un proyecto educativo basado en favorecer el uso de la biblioteca por parte de los niños/as del barrio del Bon Pastor en Barcelona, usando su creatividad como hilo conductor. Para conseguirlo se ha llevado a cabo una actividad educativa con los grupos de educación infantil y primaria de las escuelas del barrio. El material obtenido en esta actividad se ha adaptado a otros formatos para crear una instalación permanente en la biblioteca. La finalidad de esta instalación es que los usuarios encuentren en la biblioteca aquello que les permita sentir el lugar y el espacio como propios, que les permita sentirse parte activa de la vida de la biblioteca

¿Los educadores sociales tienen un lugar en la biblioteca?: el caso de la Biblioteca Bon Pastor

La Biblioteca Bon Pastor va inaugurar els seus serveis el novembre de 2004. Pocs dies després, l’assistència de grups de joves en risc va alterar el funcionament normal del centre tant per l’ús incorrecte que en feien com per la percepció que els altres usuaris tenien de la Biblioteca. Aquest article descriu la intervenció que l’equip de la Biblioteca va dur a terme durant vuit mesos, amb la participació d’un educador social integrat a l’equip com un professional més. L’experiència es planteja com un element que cal tenir en compte en el debat tècnic sobre els rols professionals.Several days after the inauguration of the Bon Pastor Library in November 2004, groups of "at-risk" youths created altercations that impaired the normal functioning of the centre, due to an incorrect use of the installations as well as to the negative impact on the perceptions of other patrons regarding the library. This article describes the activities of a team of professionals that intervened over a period of 8 months and that included a social educator together with library staff. This experience is offered as a contribution to the debate taking place about professional roles.La Biblioteca Bon Pastor inauguró sus servicios en noviembre de 2004. Pocos días después, la asistencia de jóvenes en riesgo de exclusión social alteró el normal funcionamiento del centro tanto por el uso incorrecto que hacían de las instalaciones y servicios como por la percepción que los otros usuarios tenían de la Biblioteca. Este artículo describe la intervención llevada a cabo por el equipo de la Biblioteca durante ocho meses con la participación de un educador social integrado en el equipo como un profesional más. La experiencia se plantea como un elemento a tener en cuenta en el debate técnico sobre los roles profesionales

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols